Skip to main content

About

Overview

Cidara is developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s proprietary Cloudbreak® platform enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system.

Cidara is headquartered in San Diego, California and is built on the core values of collaboration, integrity, accountability, urgency and courage which foster a unique and award-winning atmosphere.

Leadership

Management

President and Chief Executive Officer

Jeffrey Stein, Ph.D.

Dr. Stein has been President, CEO and Director of Cidara since January 2014. His team at Cidara developed the novel antifungal drug, Rezzayo, from preclinical stage to approval in the US and EU and also developed CD388, a once-per-season universal preventative for influenza, through successful Phase 2a data in partnership with Janssen Pharmaceuticals. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director Ideaya Biosciences where he chairs the compensation committee and sits on the audit committee. He was also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.
Chief Medical Officer

Nicole Davarpanah, M.D., J.D.

Dr. Davarpanah joins the Cidara team with over 10 years of experience in immuno-oncology drug development and early and late-stage clinical trial design. Prior to joining the company, she served as a Clinical and Translational Lead in Oncology at Genentech/Roche, leading the development strategy of immunotherapy combinations in bladder cancer. Prior to that role, she was the Senior Medical Director of Genitourinary (GU) Immuno-Oncology and Medical Affairs at Genentech/Roche, where she was responsible for the launch of GU oncology products, as well as cultivating strategic partnerships with disease area experts, academic institutions, regulatory agencies and professional societies.

Dr. Davarpanah is a medical oncologist and clinician who has broad experience working in multiple health care systems including academic medicine, government, and private practice. Earlier in her career, she served as a research fellow focusing on immuno-oncology and GU Cancers at the National Cancer Institute (NCI/NIH) and as a faculty member at Georgetown University School of Medicine, lecturing on the intersection of medicine, law, and technology, and serving as a national speaker and advisor to medical centers and corporations to expand health care access to life saving treatments. Dr. Davarpanah received her Doctor of Medicine degree from Boston University and her Juris Doctor degree from the University of California, Berkeley.

Senior Vice President, People and Culture

Allison Lewis, SPHR, CCP

Ms. Lewis joined Cidara in February 2015 and serves as Vice President, Human Resources responsible for all aspects of people and culture including employee engagement, compensation, organizational design, talent management, and strategic HR initiatives. She has over 15 years of diverse Human Resources experience primarily in the life sciences industry, across all stages of development and commercialization. Prior to joining Cidara, she was on the Human Resources teams at Cadence Pharmaceuticals and, subsequently, Mallinckrodt Pharmaceuticals after its acquisition of Cadence in 2014. Ms. Lewis also held HR management roles of increasing responsibility at PPD, Applied Technology and Management and IGY.

Ms. Lewis received her bachelor’s degree in Business from University of Florida and holds designations as a Senior Professional in Human Resources (SPHR), SHRM Senior Certified Professional (SHRM-SCP), and a Certified Compensation Professional (CCP). She leverages her expertise in service on the board of LifeHR, a San Diego Life Sciences HR association.

Senior Vice President, Clinical Development

Corrina Pavetto

Ms. Pavetto is an experienced clinical development professional with over 25 years of clinical research and regulatory affairs with experience in multiple therapeutic areas with a specialized focus in infectious disease. Prior to joining Cidara, Ms. Pavetto was part of the Tunnell Government Services contractor team for over 16 years supporting the development of medical countermeasures for Biomedical Advanced Research Development Authority (BARDA) at the United States Government. She was integral part of the clinical development programs for many products that have been approved, licensed or cleared by the FDA. During her tenure at BARDA, she was involved in the government public health response for the H1N1 influenza pandemic in 2009, the Zika emerging infectious disease, Ebola outbreaks in West Africa and the Operation Warp Speed effort for SARS-CoV-2 virus in the COVID-19 pandemic. She has earned prestigious recognition awards from the Secretary of Health and Human Services and the White House for these contributions. Ms. Pavetto has also served as a regulatory and clinical consultant to the pharmaceutical industry as well as held several senior level positions at contract research organizations, consulting companies, academic institutions and site management organization. Ms. Pavetto has a BS and MS degrees in science from the University of Pittsburgh as well as regulatory affairs certification from RAPS.
Chief Financial Officer

Frank Karbe

Mr. Karbe joined Cidara in 2025 as Chief Financial Officer, bringing over 25 years of experience in the healthcare industry as both a banker and a senior executive in biopharmaceutical companies. He has held leadership roles as Chief Financial Officer, President, and Chief Executive Officer, gaining expertise in corporate finance, business development, strategy, and operations. Previously, he served as CEO of Better Therapeutics, where he led the company to secure the first FDA authorization for a digital therapeutic for Type 2 Diabetes. Before that, he was President and CFO at Myovant Sciences, where he helped launch ORGOVYX for advanced prostate cancer and MYFEMBREE for uterine fibroids and endometriosis. He also spent over a decade as CFO at Exelixis, a biotechnology company focused on next-generation cancer treatments. Earlier in his career, Mr. Karbe was a Vice President in Goldman Sachs’ healthcare investment banking group and held finance roles at The Royal Dutch/Shell Group in Europe. He currently serves as a director of Phathom Pharmaceuticals and previously held board positions at Aduro Biotech and Arbutus Biopharma. He holds a Diplom Kaufmann from the WHU-Otto Beisheim Graduate School of Management in Germany.
Chief Scientific Officer

Les Tari, Ph.D.

Dr. Tari has over 19 years of experience in early stage drug discovery in both industry and academia. He has led a number of discovery programs and is an author or inventor on over 50 publications and patents. Previous to Cidara, Dr. Tari held positions of increasing responsibility at Trius Therapeutics from 2007 until its acquisition by Cubist Pharmaceuticals in 2013. At Trius, Dr. Tari led the efforts to generate and advance a novel class of dual-targeting broad spectrum antibacterial agents. Prior to Trius, Dr. Tari was a co-founder and Director of Structural Biology from 2003 to 2007 at ActiveSight Inc., where he led all research efforts in inflammation and oncology. From 2001 until 2003, Dr. Tari was a member of the scientific staff during the start-up phase of Syrrx Inc., where he participated in the design and development of the first industrial high-throughput structural genomics platform that aided in the discovery of Alogliptin, subsequently approved for the treatment of type II diabetes. Previous to his career in industry, Dr. Tari held an academic position as an Alberta Heritage Foundation Scholar for Medical Research at the University of Calgary, where he conducted research focused on antibiotic discovery. Dr. Tari holds a B.Sc. in Chemistry, and a Ph.D. in Chemistry and Structural Biology from the University of Manitoba.
Chief Operating Officer

Shane Ward

Mr. Ward joined Cidara in 2021 as Chief Legal Officer and was appointed Chief Operating Officer in 2022. He has more than 25 years of biopharmaceutical industry legal, operations, strategy, and finance experience. In his current role, he is responsible for a range of Cidara's corporate functions including Legal, IP, Healthcare Compliance, Technical Operations, Quality, and IT. As Corporate Secretary, he also coordinates board and committee activities and oversees corporate governance. Prior to joining us, Mr. Ward was Chief Legal and Strategy Officer for Bellicum Pharmaceuticals, a clinical-stage cell therapy company developing controllable CAR-T products for the treatment of solid tumor cancers. He previously held leadership roles with commercial and development-stage biotechnology and pharmaceutical companies including Gilead Sciences, Human Genome Sciences, Dynavax, and Abbott. He began his legal career in the FDA regulatory practice group of Sidley Austin, an international law firm. Mr. Ward holds an M.B.A. from Cornell University, a J.D. from Georgetown University, and a B.A. from the University of Virginia.
Chief Business Officer

Jim Beitel

Mr. Beitel joined Cidara in August 2024 and brings over 20 years of experience in life science corporate development including strategy, business development, commercialization, and finance roles for a variety of companies including biotech, commercial-stage specialty pharma, early-stage venture-backed companies, and multi-national pharmaceutical companies. Most recently, Mr. Beitel was Senior Vice President of Corporate Development at Fate Therapeutics where he served as a member of the executive team with responsibility for strategic partnering in oncology and autoimmune diseases. Prior to Fate, Mr. Beitel was Vice President of Corporate Development and Operations at Avanir Pharmaceuticals where he facilitated the company’s growth into a multi-product organization and the subsequent acquisition by Otsuka. Prior to Avanir, Mr. Beitel held various positions with increasing responsibility at Amgen, La Jolla Pharmaceutical Company, Azur Pharma, and Zacharon Pharmaceuticals. During Mr. Beitel’s career in business development at Fate and other companies, he has successfully sourced and executed partnering activities which significantly expanded company pipelines, generated over $4 billion in upfront payments and collaboration revenues, and contributed to the ability to raise over $1 billion in equity financings. Mr. Beitel holds a M.B.A. from Harvard Business School and a B.S. in Engineering from the University of Kansas.

Board of Directors

Chairperson

Dan Burgess

Mr. Burgess has more than 30 years of executive level experience in the biotechnology and pharmaceutical industries. He is currently a venture partner at SV Health Investors, Chairman and Chief Executive Officer of Pulmocide, a private biopharmaceutical company, a position he has held since May 2021. Mr. Burgess served as President and Chief Executive Officer of Therini Bio, a private biotechnology company, on a part-time basis from May 2019 to December 2021, and now serves as a board member. In 2011, he was one of the founding members of Rempex, which was subsequently acquired by The Medicines Co. in 2013 for $140M upfront, with a total potential deal value of $474M. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, which he joined in 2007. During his tenure as Chief Executive Officer, Mpex advanced its lead product Aeroquin from Phase 1 into Phase 3 clinical trials, raised substantial venture capital funding and ultimately achieved a successful exit in 2011 with its acquisition by Aptalis. The transaction with Aptalis was named by Scrip magazine as a finalist for “Deal of the Year”. Before joining Mpex, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company focused on biodefense, infectious disease and immune system disorders. Previously, he spent ten years at Gensia Sicor, which was acquired by Teva Pharmaceutical Industries Limited, where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess was a member of the Board of Directors of Santarus until its acquisition by Salix for $2.6B in 2013, served as Chairman of the board of Nabriva Therapeutics, a formerly publicly-traded biopharmaceutical company, from June 2017 until January 2025, and as a director of Arbutus Biopharma Corporation, a publicly-traded biopharmaceutical company, from March 2017 to February 2025. He is also Chairman of the Joint Oversight Board of CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, on the board of advisors for Life Science Cares San Diego, and a board member of Biocom, the California life sciences trade association. Mr. Burgess received his B.A. in Economics from Stanford University and an MBA from Harvard Business School.

Bonnie Bassler, Ph.D.

Dr. Bassler currently serves in several roles at Princeton University, including Chair of the Department of Molecular Biology since 2013, associated faculty member of the Department of Chemistry since 2010, Investigator at the Howard Hughes Medical Institute since 2005, Professor in the Department of Molecular Biology since 1994, and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler has served as a board member of Royalty Pharma plc since June 2020, as a board member of Regeneron Pharmaceuticals, Inc. since 2016, and as a Trustee of the Alfred P. Sloan Foundation since 2014, and previously served as a board member of Sanofi from November 2014 to September 2016. Dr. Bassler served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. Dr. Bassler has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society, among other honorific organizations. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.

Carin Canale-Theakston

Ms. Canale-Theakston currently serves as Chief Executive Officer of Canale Communications Inc., a life sciences communications company that she founded in May 2010. Prior to founding Canale Communications, Ms. Canale-Theakston served as President of the life sciences division of Porter Novelli, an international public relations firm, from May 2005 until May 2010. Prior to Porter Novelli, Ms. Canale-Theakston was a Partner and Managing Director of Atkins + Associates, a life sciences communication firm, from February 2000 until it was acquired by Porter Novelli in May 2005. She has also served as a member of the CONNECT (previously San Diego Venture Group), board since January 2007, including Chair in 2011-2012. Since January 2007, Ms. Canale-Theakston has served as a member and vice chair of the board of directors of BIOCOM and is currently chair of the nominating-governance committee. Ms. Canale-Theakston also serves on the advisory board for Abintus Bio and Epitracker Inc. Ms. Canale-Theakston holds a B.A. in communications and marketing from the University of Tulsa.

James Merson, Ph.D.

James Merson, Ph.D., is the Chief Virology Officer at a stealth oncology biotechnology company. He is a member of the R&D Leadership Team, leading the viral vector platform. As the former Global Therapeutic Head of Infectious Diseases at Janssen, James lead R&D that resulted in approval of Cabenuva, line extensions of Symtuza & Juluca, 5 Ph3, 10 Ph2, and 8 Ph1 studies, 9 NMEs, and in-licensing of JNJ-0953 (antiviral drug conjugate for influenza PrEP) and JNJ- 3989 (siRNA for HBV for combination with HBV a therapeutic vaccine and anti-PD1 mAb).

James held more than 30 years of R&D experience in antivirals, vaccines and immuno-oncology at Pfizer, becoming SVP and CSO of Vaccine Immunotherapeutics Research Unit. As a member of the Vaccines leadership, he contributed to the approval of Prevnar 13 & 20 and ABRYSVO, and oversaw 4 Ph1/2 studies with oncology vaccines or oncolytic viruses combined with tremelimumab and sasanlimab, 2 Ph1 studies for ant-IgE vaccine and anti-nicotine vaccine. James was responsible for starting Pfizer vaccines in 2005 with the acquisition of PowderMed and Coley Pharmaceuticals, that resulted in the acquisition of Wyeth Pharmaceuticals. James was also responsible for Pfizer’s first build-to-buy partnership with Ignite Pharmaceuticals that generated a novel armed oncolytic vaccinia virus and was evaluated in combination with sasanlimab in a Ph1 study. As Therapeutic Head, Antivirals at Pfizer, he oversaw approval of Selzentry, 4 Ph2 studies, Pfizer’s first gene therapy program for HIV with Immusol, and the in-licensing of dalbavancin and anidulafungin.

He holds a Ph.D. in Microbiology and Immunology, Baylor College of Medicine, Houston Texas and a B.A. in Biology from Bellarmine College, Louisville, KY. James has held multiple SAB and Advisor positions, consulted for several Venture Capital companies, holds 5 patents and has 48 publications.

Chrysa Mineo

Ms. Mineo led corporate development at Receptos, Inc., from 2009 to 2015, where strategic partnering efforts for Phase 3 immunology candidate ozanimod resulted in the company’s acquisition by Celgene for $7.2 billion. During her tenure,she played a key role in the Receptos initial public offering (IPO) and established product and technology collaborations with AbbVie, Ono, Lilly and Janssen. Prior to Receptos, Ms. Mineo held roles of increasing business development responsibilityat Neurocrine Biosciences from 1997 to 2009, where she led or played a primary role in negotiating and closing more than 25 transactions, including worldwide or regional product candidate collaborations from Phase 1 to registration and product in-licensing transactions. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from theUniversity of California, Davis and received her MBA from Duke University’s Fuqua School of Business. Additionally, Ms. Mineo is a Co-Founder of Alume Biosciences, a member of the Director’s Council at the Scripps Institution of Oceanography, and a member of the Board of Directors of the San Diego Natural History Museum.

Josh Resnick, M.D.

Bio Coming Soon!

Ted Schroeder

Mr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from 2018 to 2023 and as a director until March 2025, following the 2018 acquisition of Zavante Therapeutics, a company that he co-founded and served as President, Chief Executive Officer and a member of the Board of Directors. Prior to that, he was a co-founder of Cadence Pharmaceuticals and served as President, Chief Executive Officer and a member of the Board of Directors since its inception in May 2004 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. From August 2002 to February 2004, he served as Senior Vice President of North American Sales and Marketing of Elan Pharmaceuticals, a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan, a position he also held at Dura Pharmaceuticals, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the Board of Directors of Phathom Pharmaceuticals and has previously served on the boards of several public and private life sciences companies including Otonomy, Collegium Pharmaceutical, Incline Therapeutics, Hyperion Therapeutics and Trius Therapeutics. He is the former chairman the Antimicrobials Working Group, from May 2021 until the end of his term in December 2022. In 2014, Mr. Schroeder was recognized as the EY Life Science Entrepreneur of the Year for the San Diego Region and was subsequently recognized as a national finalist. He holds a B.S. in Management from Rutgers University.

Ryan Spencer

Ryan Spencer is Chief Executive Officer of Dynavax, and a member of its board of directors, where he leads the vaccine company’s mission to help protect the world against infectious diseases. He first joined Dynavax in 2005 and, during his fourteen-year ascent to CEO, served in various positions with increasing responsibility across commercial, finance, investor relations, and corporate strategy. As Senior Vice President of the commercial organization, Mr. Spencer led the successful commercial launch of the industry’s first and only two-dose hepatitis B vaccine – HEPLISAV-B® – in 2018. In December 2019, he was appointed CEO and, in the wake of the COVID-19 pandemic, led the supply of Dynavax’s CpG 1018® adjuvant for nearly 1 billion COVID-19 vaccine doses to vaccine developers around the world. Under Mr. Spencer’s tenure as CEO, the company has established HEPLISAV-B® as the leader of the adult hepatitis B vaccine market in the U.S., secured product approvals in the European Union and Great Britain, advanced three novel vaccine clinical candidates, and grown its employee base by more than 75 percent.

Prior to joining Dynavax, he served as Assistant Controller at QRS Corporation and as a member of the audit practice at Ernst & Young. Mr. Spencer is an active member of the Biotechnology Innovation Organization (BIO) and serves as a member of the board of directors for Dynavax. He earned a Bachelor of Arts in Business Economics from University of California, Santa Barbara.

Jeffrey Stein, Ph.D.

Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.

Scientific Advisors

Rick Bright, Ph.D.

Rick Bright, Ph.D. is former chief executive officer of the Pandemic Prevention Institute (PPI) at The Rockefeller Foundation. He led the development of the Foundation’s pandemic data-to-action platform that integrates modern technology, data analytics and global partners to help the world detect, prevent, and mitigate pandemic threats to achieve containment as quickly as possible. Prior to this role, he served as the Deputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority (BARDA), in the U.S. Department of Health and Human Services.

Dr. Bright has also gained extensive experience in the biotechnology industry where he served in senior leadership and executive management roles. He has held senior scientific leadership positions in non-governmental organizations where he championed innovative vaccine development and expanded vaccine manufacturing capacity to multiple developing countries. He also spent a decade in vaccine, therapeutics, and diagnostics development at the Centers for Disease Control and Prevention where he received the Charles C. Shepard Science Award for Scientific Excellence for his work.

Dr. Bright serves as an international subject matter expert in biodefense, emergency preparedness and response, pharmaceutical innovation, vaccine, drug and diagnostic development and served as an advisor to the Biden Administration, World Health Organization, the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats.

Additionally, he serves as an Executive Board Member for the NY Academy of Sciences International Science Reserve, a Sr. Fellow at the Foreign Policy Association, and a member of the Council on Foreign Relations. Dr. Bright received a Ph.D. in Immunology and Molecular Pathogenesis from Emory University and a B.S., magna cum laude in Biology and Physical Sciences from Auburn University at Montgomery.

Philip Krause, M.D.

With over 30 years of experience at the Food and Drug Administration, Philip Krause, M.D. has a unique combination of scientific, regulatory, clinical, and public health experience. He is a long-time supporter of CASSS and WCBP and has co-chaired the meeting several times. Dr. Krause is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development.

He currently serves as an independent consultant, providing strategic and regulatory advice related to biological product development. Previously, he was a deputy director of FDA’s Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US over the past 10 years.
Dr. Krause received an M.D. from Yale Medical School, an MBA from Florida State University, and a B.S. and M.S. in Computer Science from the University of Illinois.

Mario Barro, Ph.D.

Mario Barro, Ph.D. is a Venture Partner and Head of the Infectious Disease Team at RA Capital Management, where he spearheads early-stage investment, company creation, and leads the Infectious Diseases team in advancing the company's evidence-based investment strategy. In this capacity, Mario collaborates closely with several portfolio companies, serving as a Board Member or Technical Advisor. With over three decades of experience in vaccinology, virology, and immunology across large pharma, government, academia, and biotech sectors, he brings a wealth of expertise to his roles.

In addition to his work at RA Capital, Mario is the CEO and co-founder of GIVAX, a vaccine development startup focused on eradicating preventable Gastrointestinal infections in children and adults. As CEO, he drives the development of a novel groundbreaking vaccine solution aimed at addressing a critical unmet medical need.
Before joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur, where he led a team responsible for integrating influenza vaccine development with cutting-edge technologies like machine learning and antigen design. He also held a pivotal role as Project Director at BARDA, where he managed the technical selection and successful execution of multiyear, multimillion-dollar vaccine development programs, including efforts toward a Universal Flu Vaccine.

Mario completed his postdoctoral training at the NIH/NIAD and Mount Sinai School of Medicine and received a Ph.D. in microbiology from the University of Chile.

Frederick G. Hayden, M.D., FACP

Frederick Hayden, MD, FACP is Stuart S. Richardson Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine at the University of Virginia School of Medicine in Charlottesville, Virginia. Dr. Hayden joined the faculty of the University of Virginia in 1978, became Richardson Professor in 1990, and transitioned to emeritus status in 2015. From 2006-2008, he served as a medical officer in the Global Influenza Programme at the World Health Organization, Geneva and as influenza research coordinator at the Wellcome Trust, London from 2008-2012.

His principal research interests have been on respiratory viral infections with a particular focus on the development and application of antiviral agents for influenza, rhinovirus, and coronavirus infections. He has contributed to the development of seven influenza antivirals and two vaccines approved for clinical use in one or more countries. During the COVID-19 pandemic he collaborated with colleagues in China to conduct the first controlled trials of candidate antivirals in hospitalized patients and has served as a consultant to platform studies (UK CTAP, ACTIV, AGILE), academic groups, and industry regarding the selection of therapeutics for clinical trials. He has published over 450 peer-reviewed papers, chapters, and other articles, and co-edited the textbook Clinical Virology. In 2019, Dr. Hayden received the Lifetime Achievement Award for Influenza Research from International Society for Influenza and Other Respiratory Viral Diseases.

He received an MD from Stanford University School of Medicine in 1973 and completed his clinical training in internal medicine and infectious diseases at Strong Memorial Hospital, University of Rochester, New York.

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121

p: (858) 752-6170
e: info@cidara.com

ABOUT

PIPELINE

CLOUDBREAK®

PUBLICATIONS

NEWSROOM

INVESTORS

CAREERS

Subscribe

© 2025 Cidara Therapeutics, Inc. | Terms of Use | Privacy and Cookies Policy